In the midst of a profound restructuring of the global innovative drug supply chain, China’s pharmaceutical industry is stepping onto the world stage at an unprecedented pace. For patients worldwide battling chronic and life-threatening diseases, this shift means more than just numbers—it’s about hope, better options, and lives transformed.

In 2025, China’s outbound licensing (license-out) deals for innovative drugs officially surpassed $100 billion, signaling a structural transformation from “import and adapt” to becoming a key “global supplier.” According to data from global consulting firm SAI MedPartners, in the first half of 2025, China-related pharmaceutical business development (BD) transactions accounted for nearly half of the global total. SAI MedPartners’ Asia President, Deng Xianpeng, noted: “By the end of 2025, China’s innovative drug BD transaction volume is expected to exceed $100 billion.”

This projection has been swiftly validated by market data. A report from a domestic pharmaceutical data platform in October, titled “2025 Q1–Q3 Pharmaceutical Transaction Trends Analysis,” shows that in the first three quarters of 2025, China’s license-out total reached $92.03 billion. Including the blockbuster collaboration between Innovent Biologics and Japan’s Takeda Pharmaceutical in October, the total has officially crossed the $100 billion threshold (approximately RMB 7,061 billion).

Disease Burden and Unmet Needs: Why AKT is Back in the Spotlight?

From a patient’s perspective, the rising burden of cancers like breast, prostate, ovarian, and endometrial—often linked to the AKT pathway—feels deeply personal. Imagine a woman diagnosed with advanced breast cancer, facing not just the physical toll but the emotional weight of limited treatment options after initial therapies fail.

According to GLOBOCAN 2024, global new cancer cases exceed 20 million annually, with breast cancer consistently topping the incidence charts. In advanced or resistant stages, abnormal activation of the PI3K/AKT/mTOR pathway is a key driver of treatment failure and disease progression.

While targeted and immunotherapies have improved outcomes for some, significant pain points remain:

• Hormone receptor-positive (HR+) breast cancer after endocrine therapy resistance
• Solid tumors failing multiple lines of treatment
• Patient populations limited by the toxicity of PI3K inhibitors

The burning question for patients and clinicians alike: “How can we inhibit this pathway while ensuring safety and long-term benefits?” This is the crux of whether AKT-targeted therapies can truly make a difference in real lives.

Target Mechanism and Clinical Data: The Science Behind AKT Inhibition

The AKT pathway is the central hub in the PI3K/AKT/mTOR signaling axis, with isoforms AKT1, AKT2, and AKT3 playing pivotal roles in tumor cells:

• Proliferation
• Survival
• Metabolic reprogramming
• Treatment resistance

Compared to earlier PI3K inhibitors, next-generation AKT inhibitors focus on:

• More precise isoform targeting
• Manageable pathway-related toxicities like rash and hyperglycemia
• Potential for combination with endocrine or chemotherapy regimens

Take Capivasertib, which has broken through in international markets, as an example. In Phase III trials for HR+/HER2− breast cancer patients, it showed:

• Significantly superior median progression-free survival (PFS) compared to controls
• Even more pronounced efficacy in biomarker-specific subgroups

For patients, this translates to more time—time with family, time pursuing dreams, time free from the shadow of progression. It’s this kind of data that reignites hope and prompts global pharma to reassess AKT’s viability. Chinese companies launching next-gen candidates in this space, with differentiators in efficacy windows, safety, or dosing, hold clear potential for global partnerships that could reach patients faster.

Market Potential and Commercialization: Why Global Pharma is Betting Big?

From a market view, the AKT-related cancer treatment landscape is transitioning from theoretical promise to tangible products. But for patients, it’s about accessibility: a world where innovative treatments aren’t just for the few, but options for many.

Comprehensive forecasts from firms like Wiseguy Reports and GlobalData predict:

• The global AKT pathway drug market will sustain mid-to-high single-digit to double-digit growth over the next 5–8 years
• Breast cancer remains the core commercialization indication
• Combinations with CDK4/6 inhibitors and endocrine therapies are seen as the highest-volume scenarios

Notably, China lacks a mature AKT-targeted product lineup, and globally, only a handful are in late-stage or commercialized. This “high demand, low supply” gap fuels high-value BD deals, bringing cutting-edge therapies to patients who need them most.

The $100 Billion Milestone: Three Deals Shattering Records in China’s Drug Outbound Journey

This $100 billion isn’t abstract—it’s built on groundbreaking deals that could change patient stories worldwide:

• In May, Sunshine Pharmaceutical and its affiliate licensed their original drug SSGJ-707 to Pfizer. The deal included a $1.25 billion upfront payment, up to $4.8 billion in milestones, and tiered royalties—setting a record for upfront payments in Chinese outbound licensing.
• In July, Hengrui Medicine partnered with GSK, granting global rights (ex-China) to PDE3/4 inhibitor HRS-9821 and options for up to 11 projects. Upfront: $500 million; potential total: up to $12.5 billion.
• Announced in October and effective December, Innovent Biologics’ global strategic collaboration with Takeda on next-gen immuno-oncology (IO) and ADC therapies totaled $11.4 billion. A Morgan Stanley November report called it the largest single oncology outbound deal by total value in Chinese history.

Within半年, three outbound records were shattered, signaling China’s role as a “global pharmacy” for innovative drugs—delivering hope to patients everywhere.

Market and Commercialization Logic: From Single-Product Deals to Systemic Collaborations

BD is evolving from isolated product licenses to collaborative global R&D ecosystems. As Leopard Research Institute’s healthcare analyst Liang Kunyuan explains, drivers include:

On one side, big pharma faces a “patent cliff,” with Fangzheng Securities projecting $200 billion in annual sales at risk by 2030. On the other, Chinese firms have built high-quality, internationally verifiable clinical assets through years of R&D.

Tumor and immunology lead the charge, with ADC and bispecific antibodies surging since 2023. Metabolic and obesity therapies follow, exploding around GLP-1 and multi-target agents in 2025. Autoimmune, rare diseases, and select CNS areas are heating up too.

For patients, this means faster access to diverse, effective treatments—turning “survival” into “thriving.”

Company Profiles and Partnership Logic: R&D Depth Meets Global Reach

These deals reflect clear divisions: Chinese biotechs drive R&D with:

• Robust early molecule design and translation
• Efficient domestic clinical validation
• Deep expertise in specific targets

Global pharma brings:

• Multicenter trials
• Worldwide regulatory affairs
• Market access and sales networks

It’s risk-sharing that amplifies value, embodying China’s “rational outbound” strategy—and ultimately benefiting patients with safer, more effective options.

Industry and Policy Lens: A Decade of Systemic Reforms

Over the past decade, China’s pharma landscape has undergone transformative reforms:

• 2015: Drug review and approval system overhaul begins
• 2018: Clinical trial approvals shift to implicit consent
• 2020: Breakthrough therapy designation implemented
• 2021: “Dual-channel” reimbursement boosts innovative drug access
• 2022: Accelerated review for listings, emphasizing clinical value
• 2025: “Measures to Support High-Quality Innovative Drug Development” forms full-chain support

These aren’t isolated changes but a cohesive evolution from efficiency to value-driven innovation. As China Healthcare Security Research’s Liang Jialin summarizes, China has leaped from generics dominance to innovation activation, now outputting globally valuable assets.

Conclusion

The resurgence of AKT targeting exemplifies China’s shift: no longer chasing hotspots, but carving breakthroughs in established yet unsolved areas. For patients, it’s a beacon—from mere access to meaningful choices.

This collaboration isn’t aggressive expansion but confident positioning in global innovation. Companies like Hong Kong-based DengYueMed exemplify this, with unwavering commitment to quality, compliance, and integrity. Anchored in excellence, innovation, sustainability, and social responsibility, they bridge Chinese innovations to international markets, enhancing global patient access and choices.

As patients worldwide move from “having medicine available” to “having better options to choose from,” China’s innovations are an indispensable force—and international export leaders stand at this pivotal juncture, fostering real-world impact.

References

1. GLOBOCAN 2024. Global Cancer Statistics.
2. Nature Medicine. Targeting the PI3K–AKT pathway in cancer.
3. NEJM. Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer.
4. Wiseguy Reports. Global AKT Inhibitor Market Forecast.